Company Overview
Jaguar Health, Inc. operates as a commercial-stage pharmaceuticals company dedicated to developing plant-based prescription medicines designed to alleviate gastrointestinal distress in both human patients and animals. The enterprise functions within the broader Healthcare sector and specifically targets the Biotechnology industry, where its focus lies in the research and commercialization of specialized therapeutic agents. As of the latest reporting period, the company maintains a market capitalization of $3.84M, generates annual revenue of $11.79M, and employs a workforce of 49 individuals. The combination of a sub-$4M market cap and revenue figures slightly exceeding $11M indicates that Jaguar Health occupies a niche position with limited scale relative to large-cap pharmaceutical peers, suggesting a business model that relies on high-margin, specialized product lines rather than broad-market volume sales.
Financial Health
The company reported revenue of $11.79M over the trailing twelve months, yet this revenue generated a net income of -$40,293,000, revealing a cost structure where operating expenses significantly exceed total revenue. This negative net income corresponds with an EBITDA of -$30,909,000, indicating that the core operations are currently burning cash despite generating top-line sales. Free cash flow stands at -$15,181,375, which implies that the company is utilizing its existing cash reserves to fund operations and development rather than generating surplus liquidity for debt reduction or shareholder returns. The company holds $3.53M in cash against $31.90M in debt, resulting in a debt-to-equity ratio of 731.82, which characterizes the balance sheet as highly leveraged and reliant on future financing or operational turnaround to meet obligations. Profitability metrics reflect this financial stress, with a gross margin of 81.9% demonstrating strong pricing power or low cost of goods sold, contrasted sharply by an operating margin of -234.8% and a profit margin of 0.0%. The return on equity is calculated at -411.6% and the return on assets sits at -38.0%, metrics that indicate that management is currently deploying capital in a manner that destroys value rather than generating positive returns. Furthermore, the current ratio of 0.81 suggests that the company possesses fewer current assets than current liabilities, signaling potential short-term liquidity challenges as it seeks to settle its immediate financial commitments.
Valuation Assessment
Valuation multiples for Jaguar Health reflect its lack of profitability, with a trailing P/E ratio listed as N/A and a forward P/E of -0.06, implying that traditional earnings-based valuation models are not applicable and that the market is pricing the stock based on assets or future potential rather than current earnings. The price-to-book ratio is 0.40, indicating that the market values the company at less than half of its book value, which often suggests the market perceives significant risks or that the asset base may be undervalued relative to the equity claims. Alternative valuation metrics further highlight the company's financial distress, as the price-to-sales ratio is 0.33 and the EV/EBITDA is -1.00, suggesting that the stock is priced at a deep discount relative to its sales and adjusted earnings. Regarding trading range volatility, the 52-week high was $15.48 and the 52-week low was $0.34, meaning the current price sits significantly closer to the bottom of the trading range, reflecting a prolonged period of depressed valuation. The beta value is recorded at 0.05, which indicates that the stock price exhibits extremely low volatility relative to the broader market, moving independently of general market trends and suggesting a defensive or speculative characteristic rather than a cyclical one.
Growth & Income
Revenue growth for the year-over-year period was -0.8%, while earnings growth is listed as N/A, indicating that the company is currently shrinking rather than expanding its top line and has no positive earnings trajectory to measure. Because earnings are negative, the concept of earnings growth is not applicable in the traditional sense, and the decline in revenue suggests a contraction in the commercialization of its plant-based medicines. Regarding income distributions, the company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the company retains all its earnings (or rather, its losses) to attempt to fund operations and development initiatives. Consequently, the overall growth and income profile for Jaguar Health is defined by revenue contraction and a total absence of income generation, leaving shareholders with no current yield and exposure to a shrinking revenue base as the company navigates its commercial-stage challenges.